Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||CETP Inhibition in CVD prevention: an actual appraisal|
|Author:||Di Bartolo, B.|
|Citation:||Current Cardiology Reports, 2016; 18(5):43-1-43-6|
|Belinda Di Bartolo, Kohei Takata, MyNgan Duong, Stephen J. Nicholls|
|Abstract:||By virtue of their effects on low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and cellular cholesterol efflux, there is considerable interest in the potential use of pharmacological inhibitors of cholesteryl ester transfer protein (CETP) as a novel approach for cardiovascular disease prevention. This is supported by observations from genetic and animal studies suggesting that less CETP activity has favorable cardiovascular effects. Despite the adverse effects of the first CETP inhibitor to move forward in clinical development, torcetrapib, there remains considerable interest in developing alternative CETP inhibitors without the off-target effects of torcetrapib. The clinical development programs leading to a number of promising CETP inhibitors will be reviewed.|
|Keywords:||CETP inhibitors; lipids; cardiovascular disease; prevention; clinical trials|
|Rights:||© Springer Science+Business Media New York 2016|
|Appears in Collections:||Agriculture, Food and Wine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.